Elekta AB
EJXB
Company Profile
Business description
Sweden-based Elekta develops, manufactures, and distributes treatment planning systems for neurosurgery and radiotherapy, including stereotactic radiosurgery and brachytherapy. The company has an installed base of more than 7,300 linear accelerators, Gamma Knife and Unity platforms, as well as brachytherapy installations. The company's sales are evenly distributed across geographies, with North and South America accounting for 30%; Europe, the Middle East, and Africa accounting for 36%; and the Asia-Pacific contributing the remainder.
Contact
Hagaplan 4
Box 7593
Stockholm11368
SWET: +46 858725400
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
30 April 2026
Employees
4,485
Stocks News & Analysis
stocks
BlackRock earnings: Market gains and inflows drive AUM and revenue to record highs
We plan to raise our fair value estimate of BlackRock stock.
stocks
Our view of ANZ’s strategic plan
Trying to please customers and shareholders with a simpler and leaner bank.
stocks
Perplexing buyback from overvalued ASX share
Earnings continue to grow but investor expectations are too high.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 9,299.00 | 21.90 | 0.24% |
CAC 40 | 8,106.88 | 187.26 | 2.36% |
DAX 40 | 24,252.80 | 15.86 | 0.07% |
Dow JONES (US) | 46,270.46 | 202.88 | 0.44% |
FTSE 100 | 9,450.96 | 1.81 | -0.02% |
HKSE | 25,978.11 | 536.76 | 2.11% |
NASDAQ | 22,521.70 | 172.91 | -0.76% |
Nikkei 225 | 47,672.67 | 825.35 | 1.76% |
NZX 50 Index | 13,307.40 | 30.41 | 0.23% |
S&P 500 | 6,644.31 | 10.41 | -0.16% |
S&P/ASX 200 | 8,990.90 | 22.20 | 0.25% |
SSE Composite Index | 3,912.21 | 46.98 | 1.22% |